Tumor neoantigen-peptide Major Histocompatibility Complex (Neoantigen-MHC)

Tumor neoantigen-peptide Major Histocompatibility Complex (pMHC) represents a critical class of tumor-specific targets for cancer immunotherapy. These complexes are formed when somatic mutations in a tumor's genome result in novel protein sequences, which are then processed into short peptide fragments and presented on the cell surface by MHC class I or II molecules. Because these neoantigens are absent from healthy tissues, they allow the immune system to specifically identify and destroy malignant cells while sparing normal ones. The recognition of these pMHC complexes by T-cell receptors (TCRs) is the fundamental step in the adaptive immune response against cancer. Therapeutic strategies targeting these complexes include personalized neoantigen vaccines, which prime the immune system to recognize specific mutations, and adoptive T-cell therapies, which use engineered TCRs to target the pMHC directly. Despite their potential, challenges such as tumor heterogeneity, HLA downregulation, and the risk of cross-reactivity with self-antigens remain significant hurdles in the clinical application of neoantigen-targeted therapies.

Other names

Neoepitope-MHC complexTumor-specific antigen-MHC complexpMHC complexNeoantigen-HLA complexTumor-specific peptide-MHC

T-cell receptor (TCR) mediated recognition of the peptide-MHC complex on the tumor cell surface, leading to the activation of cytotoxic T lymphocytes (CTLs) and subsequent tumor cell lysis.